Halozyme Therapeutics — May 6, 2025 release

For the full year 2025, the Company expects: • Total revenue of $1,200 million to $1,280 million, representing growth of 18% to 26% over 2024 total revenue, primarily driven by increases in royalty revenue. Revenue from royalties of $750 million to $785 million, representing growth of 31% to 37% over 2024. • Adjusted EBITDA of $790 million to $840 million, representing growth of 25% to 33% over 2024. • Non-GAAP diluted earnings per share of $5.30 to $5.70, representing growth of 25% to 35% over 2024. The Company’s earnings per share guidance does not consider the impact of potential future share repurchases. Table 1. 2025 Financial Guidance   Previous Guidance Range New Guidance Range Total Revenue $1,150 to $1,225 million $1,200 to $1,280 million Royalty Revenue $725 to $750 million $750 to $785 million Adjusted EBITDA $755 to $805 million $790 to $840 million Non-GAAP Diluted EPS $4.95 to $5.35 $5.30 to $5.70 1 Adjusted EBITDA and non-GAAP Diluted EPS are non-GAAP financial measures. See “ Note Regarding Use of Non-GAAP Financial Measures ” below for an explanation of these measures. Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the first quarter ended March 31, 2025 today, Tuesday, May 6, 2025, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: https://registrations.events/direct/Q4I7813723 . The call will also be webcast live through the “Investors” section of Halozyme’s corporate website and a recording will be made available followin